As they lagged expectations, tech stocks have been one of the biggest stories of the stock market for the last few months. But have you noticed that tech is starting to finally turn around?

'Investor Anxiety' On Software Stocks Prevails, But This Analyst Sees Hope In A Few Stocks, With Questions Around Others -- Like Palantir

06:19pm, Monday, 15'th Aug 2022 Benzinga

On average, software companies beat Q2 revenue estimates by 2% and profitability expectations by 5%, RBC analyst Matthew Hedberg said. Q3 was guided lower for both revenue and profitability while

IPO Stock Of The Week: Security Leader HireRight Approaches Fresh Buy Point

02:53pm, Friday, 12'th Aug 2022

Among the top IPO stocks to buy and watch in the current stock market rally, security leader HireRight is approaching a buy point. The post IPO Stock Of The Week: Security Leader HireRight Approaches

Why Avalo Therapeutics Surged 32%; Here Are 111 Biggest Movers From Yesterday

07:52am, Wednesday, 10'th Aug 2022 Benzinga

Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 60.1% to settle at $7.27 on Tuesday after the company was granted US patent for an air treatment system and method. BBQ Holdings, Inc. (NAS

What 5 Analyst Ratings Have To Say About Qualys

06:26pm, Tuesday, 09'th Aug 2022 Benzinga

Over the past 3 months, 5 analysts have published their opinion on Qualys (NASDAQ:QLYS) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company'

Why Verona Pharma Is Trading Higher By Around 84%, Here Are 85 Stocks Moving In Tuesday's Mid-Day Session

05:26pm, Tuesday, 09'th Aug 2022 Benzinga

Gainers Verona Pharma plc (NASDAQ: VRNA) shares jumped 83.6% to $12.70 after the company announced ensifentrine met its primary endpoint and secondary endpoints in the Phase 3 ENHANCE-2 trial for CO

Qualys, ShockWave Medical, News Corporation And Some Other Big Stocks Moving Higher On Tuesday

03:39pm, Tuesday, 09'th Aug 2022 Benzinga

Verona Pharma plc (NASDAQ: VRNA) shares jumped 83.6% to $12.70 after the company announced ensifentrine met its primary endpoint and secondary endpoints in the Phase 3 ENHANCE-2 trial for COPD. The c

Qualys (QLYS) Q2 Earnings and Revenues Surpass Estimates

10:05pm, Monday, 08'th Aug 2022 Zacks Investment Research

Qualys (QLYS) delivered earnings and revenue surprises of 11.25% and 2.01%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Qualys, Inc. (QLYS) CEO Sumedh Thakar on Q2 2022 Results - Earnings Call Transcript

08:30pm, Monday, 08'th Aug 2022

Qualys, Inc. (NASDAQ:QLYS ) Q2 2022 Results Conference Call August 8, 2022 5:00 PM ET Company Participants Blair King - Investor Relations Sumedh Thakar - President and Chief Executive Officer Joo Mi

Qualys (QLYS) Q2 Earnings and Revenues Surpass Estimates

07:34pm, Monday, 08'th Aug 2022

Qualys (QLYS) delivered earnings and revenue surprises of 11.25% and 2.01%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Qualys Stock Rises As Earnings Guidance Tops Estimates

04:38pm, Monday, 08'th Aug 2022

Qualys stock climbed on second-quarter earnings and revenue that topped analyst estimates while earnings guidance came in above views. The post Qualys Stock Rises As Earnings Guidance Tops Estimates a

Qualys (QLYS) Earnings Expected to Grow: Should You Buy?

02:01pm, Monday, 01'st Aug 2022 Zacks Investment Research

Qualys (QLYS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Top Fintech Company

featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by